Erythropoietin gene therapy - Valentis
Alternative Names: EPO/Switch; EpoSwitch; EpoSwitch GeneMedicineLatest Information Update: 19 Sep 2008
At a glance
- Originator Valentis
- Class Antianaemics; Gene therapies; Recombinant erythropoietins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anaemia
Most Recent Events
- 19 Sep 2008 Updated MoA
- 24 May 2001 Erythropoietin gene therapy in combination with EPOSwitchTM is available for licensing (http://www.valentis.com/)
- 06 Jun 2000 Preclinical development for Anaemia in USA (IM)